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Abstract 
Background: Promising results for mammary carcinoma treatment with photodynamic therapy (PDT) presuppose 
a careful selection of irradiation light wavelength. 
Methods: 4T1 tumors implanted in NOD-SCID mice were treated with Metvix-PDT under 625 nm, 660 nm and 
their combination light, for a fixed radiant exposure. The therapeutic outcome was assessed through Monte Carlo 
based computational simulations along with a preliminary in vivo study, where fluorescence, size and 
temperature measurements were conducted. 
Results: The light source combination protocol presents great potential, since it results in high cytotoxic products 
levels and reduced treatment times; while the in vivo findings, regarding the harvested tumor mass, also support 
this hypothesis. The irradiation with 625 nm beam alone presented better results for most of the in vivo measured 
parameters. The mouse treated with only the 660 nm light source had the highest un-photobleached 
photosensitizer (PS) signal, the lowest body temperature, the heaviest harvested tumor and the lowest estimated 
concentration of PDT cytotoxic products. 
Conclusions: The use of 625 nm irradiation light matches the PS excitation band but is preferable only for 
treatment of superficial tumors. For deeper laying masses, the simultaneous use of longer wavelengths enhances 
the therapeutic outcome due to their increased penetration depth. 
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1 Introduction 
Photodynamic therapy (PDT) has been used in 
cancer treatment research since 1978 [1]. It aims to 
tumor regression and eradication based on three main 
aspects: light, photosensitizing drug (PS) and 
molecular oxygen (
3
O2). The drug, topically or 
systemically administrated to the patient, is 
selectively absorbed by tumor cells. The irradiation 
that follows with light of appropriate wavelength (λ) 
leads to formation of cytotoxic products, which 
induce cancer cell death via apoptosis, necrosis, 
autophagy or regulated necrosis (e.g. parthanatos) 
[2,3]. The combination of the light fluence rate and 
PS type strongly affect the cell death mechanism [4]. 
Even though PDT is mostly used in cases of 
superficial tumors, intravenously injected PSs and 
fiber optics allow also treatment of deep located 
cancer [5]. This is advocated by the essential PDT 
advantage of sparing adjacent healthy tissue, since the 
PS molecules are mainly concentrated in the 
malignant area and remain inactivate until 
illuminated. 
Another important advantage of topically-
administrated photosensitizing agents is the reduced 
systemic toxicity as well as the decreased 
accumulation in organs like liver. On the other hand, 
the drug has to go through skin layers reducing its 
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final amount, making the exact and fast calculation of 
its concentration and dosimetry a puzzling procedure. 
Furthermore, in the effort for accurate dosimetry one 
should account the rather complex light distribution 
inside tissues and the even more complicated tumor 
oxygenation. Light and PS dosimetry in PDT remain 
open research fields, although plenty of studies are 
available in literature [6–9]. 
As it is well known, the light is mainly 
characterized by its wavelength. Different λ values 
result in different type of interactions with tissues and 
thus, different light penetration depths. The main 
tissue parameters that affect penetration are 
absorption and scattering coefficients (μα and μs, 
respectively), anisotropy factor (gf) and refractive 
index (n). A careful literature overview for the above 
values reflects the difficulty in gathering all the 
available data that are necessary to implement an 
accurate computational PDT simulation. 
The sensitizing drug’s interactions with the 
irradiating beam and its pharmacokinetic properties 
also affect PDT dosimetry. These are quantified in the 
form of parameters whose precise values are not yet 
fully known [10], while some of them are discussed 
in section ―2.3 Simulation model”. In brief, the 
appropriate irradiation light efficiently excites the PS 
molecules from ground to triplet energy state through 
intersystem crossing procedures. From there they can 
transfer their energy excess to molecular oxygen and 
convert it to its singlet, cytotoxic form (
1
O2) in a 
procedure called Type II mechanism [10]. 
4T1, a highly tumorigenic cell line, produces 
mammary tumors which can spontaneously 
metastasize from the primary to multiple distant sites 
[11]. With breast cancer being the most frequently 
diagnosed women’s malignancy and also a leading 
cause of cancer death [12], and since 4T1 cell line has 
been little explored from a PDT perspective, its study 
deserves the attention of researchers [13,14]. Hence, 
the main objective of this article is to present a 
computational simulation on the investigation of the 
use of different light wavelengths in the PDT 
treatment of mammary carcinoma in mice. A 
preliminary in vivo study was also implemented in 
order to assist the in silico assessment. The results 
regarding fluorescence, tumor size and temperature 
variations are given for all the post-treatment period. 
 
2 Materials and Methods 
2.1 Brief protocol description 
PDT for breast carcinoma scenarios (4T1 cells) in 
NOD severe combined immunodeficient (SCID) mice 
was investigated. Four different irradiation protocols 
were incorporated, with the light parameters being 
presented in Table 1. In order to study the effect of 
each excitation wavelength on the therapeutic 
outcome, three mice received the same radiant 
exposure (H), which was set at approximately 100 
J∙cm-2 [15,16]. It should be also noticed that fluence 
rate values (φ) for 4T1 PDT in literature range up to 
~400 mW∙cm-2 [17] but in this study were limited to 
~200 mW∙cm-2, according to the PS’s Summary of 
Product Characteristics (SmPC) [18] and to each 
source’s, used in the preliminary in vivo experiment, 
available power. The radiant exposure was controlled 
by adjusting the irradiation time. The control mouse 
(No. 4) was not irradiated. 
 
2.2 Photosensitizer 
The PS studied was Metvix cream (Galderma, 
France), since its lipophilicity offers relatively deep 
penetration into tumors [19,20]. This second 
generation PS contains methyl aminolevulinate 
(MAL), as hydrochloride (C6H11NO3•HCl) (160 
mg/g) and among others, cetostearyl alcohol (40 
mg/g), methyl parahydroxybenzoate (2 mg/g), propyl 
parahydroxybenzoate (1 mg/g) and arachis oil (30 
mg/g) [18]. Metvix presents excitation maxima at 405 
and 635 nm [10]. The methyl aminolevulinate 
contained is metabolized to intracellular porphyrins, 
including Protoporphyrin IX (PpIX), which is highly 
photosensitive and mainly accumulates in tumor 
rather in healthy cells [4]. 
 
 
 
Table 1 Treatment protocol for each mouse 
Parameter Mouse No. 1 Mouse No. 2 Mouse No. 3
a
 
Mouse No. 4 
(Control) 
λ (nm) 625 660 660 625 - 
P (mW)
b
 47.5 157 157 47.5 - 
φ (mW∙cm-2)c 60.5 199.9 199.9 60.5 - 
H (J∙cm-2) 99.9 102 50.3 49 - 
a Mouse No. 3 was irradiated simultaneously with the laser and the LED source. Each column represents the values of the relevant source. 
b At the end of the fiber. The power difference of the two light sources is a result of their maximum P value available. 
c At the tissue surface. 
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2.3 Simulation model 
The simulation was based on an improved version 
of a former published code [21,22]. The 
computational therapeutic scheme was assessed via 
Type II PDT mechanism. Although the mathematical 
model describing this mechanism is rather complex, it 
can be simplified in the following equations’ set [7]: 
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In the these equations [S0] stands for the 
concentration of ground-state photosensitizer, (t) for 
irradiation time, (ξ) corresponds to specific oxygen 
consumption rate, (ζ) to specific photobleaching ratio, 
(φ) represents the light fluence rate, (δ) low 
concentration correction, [
3
O2] concentration of 
molecular oxygen, (β) oxygen quenching threshold, 
(g) oxygen supply rate to tissue, [
3
O2]0 initial 
concentration of molecular oxygen, [
1
O2]rx 
concentration of singlet oxygen leading to cell death 
(apparent reacted singlet oxygen) and (f) the fraction 
of 
1
O2 interacting with target. In this study the 
threshold concentration of singlet oxygen leading to 
cell death [
1
O2]rx,sh was set at 500 μM.  The spatial 
profile of the fluence rate was obtained by a Monte 
Carlo algorithm (mcxyz.c, version July 22, 2019, 
created by Jacques S., Li T., and Prahl S., available 
from: https://omlc.org/software/mc/mcxyz/index. 
html), for 2 million photons. 
The model reproduced a cube of edge length of 2 
cm, whose upper 0.3 cm represented air and the rest 
parietal peritoneum muscle tissue. A 0.5 cm – radius 
tumor volume was assumed to be at the upper central 
area of the structure, with the first 0.3cm projecting 
outside muscle tissue. It also incorporated a healthy 
skin layer with thickness d = 220 μm that included 
epidermis and dermis, based on literature values 
[23,24]. Its absorption and scattering coefficients 
were extracted from Refs. [25,26]. The skin scattering 
anisotropy factor, which accounts for the scattering 
angles of photons travelling into tissue, was set at 0.8 
and the refractive index at 1.4, based on a former 
study of ours [22]. The corresponding values for the 
parietal peritoneum muscle tissue were extracted from 
Refs. [27,28]. As far as the optical properties of 4T1 
cells are concerned, it was not possible to find in 
literature values corresponding to the irradiation 
wavelengths used. Therefore, μa and μs tumor values 
were extracted by interpolation of data available in 
Refs. [29,30]. They were based on the trendlines of 
the coefficients’ graphs of Ref. [31], and are 
presented in Table 2. The corresponding values for 
the 405 nm source were extracted from available data 
of Ref. [26]. Moreover, since n is related to protein 
concentration and because cancerous tissues present 
higher protein concentration values than healthy ones 
its value was fixed at 1.54 [22]; while gf was fixed at 
0.9 [22]. Since the PS cream used leads to PpIX 
formation, its contribution to optical properties of the 
tumor area was taken into account and its optical 
properties were extracted from literature [32,33]. For 
the simulation total absorption and scattering 
coefficients at tumor site were calculated as: μa = 
μa,4Τ1 + μaPpIX and μs = μs,4Τ1 + μsPpIX, respectively [34]. 
The photochemical parameters used in the 
computational simulations correspond to those of 5-
aminolevulinic acid PpIX (ALA-PpIX), as MAL is 
demethylated by esterases to ALA [35]. They were 
extracted from Refs. [7,10,36] and are presented in 
Table 2. As the average administered PS mass to 
each mouse was 30 mg (corresponding to m = 4.8 mg 
of methyl aminolevulinate, as hydrochloride), it 
formed a cylinder with height h ≈ 0.1 cm and radius r 
≈ 0.8 cm, and because the molar mass (Mr) of methyl 
aminolevulinate hydrochloride is 181.62 g/mol [37], 
the initial PS concentration on skin surface [S0] was 
estimated at 131 mM, using Equation 4: 
[  ]  
 
      
                                      ( ) 
A correction factor of 0.1 was applied to the [S0] 
value to take into account the worst case scenario of 
Parafilm removal by the mice during the 3 h dark 
interval for PS absorption, as well as resultant PS 
loses (e.g. PS remains on the glove of application and 
on mice hair). Moreover, according to the PS’s SmPC 
[18], in vitro studies in human skin revealed a dermal 
depot containing 4.9% of the radiolabelled MAL 
administered dose, although, as stated ―in humans, a 
higher degree of accumulation of porphyrins in 
lesions compared to normal skin has been 
demonstrated with Metvix cream‖. Therefore, in this 
study, after the dark period and the area cleaning with 
saline, the PS absorption through skin was set at 5% 
of the surface concentration. Furthermore, to account 
for the PpIX build up during the dark period as a 
function of depth, the trendline of the relevant data 
available in a 2016 study of Campbell et al. [32] was 
extracted and used. Finally, the PpIX molecules were 
assumed to have accumulated only in tumor tissue. 
All the above mentioned calculations were 
implemented through scripts coded in MATLAB 
software (The MathWorks, Inc., Natick, MA, United 
States), using a desktop computer with an Intel® 
Core™ i7 – 4790 @ 3.60 GHz processor and 16 GB 
of RAM.  
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Table 2 Optical and photochemical parameters of the simulation model. 
Optical parameters 
a
 Photochemical parameters 
b
 
Layer Parameter 
Value 
@ 405 nm 
Value 
@ 625 nm 
Value 
@ 660 nm 
Parameter Value 
Skin μa 2.86 cm
-1
 0.33 cm
-1
 0.20 cm
-1
 ε 0.003 (cm-1 μΜ-1) 
 μs 113.9 cm
-1
 166.4 cm
-1
 165 cm
-1
 ξ 3.7 ∙ 10-3 (cm2 mW-1 s-1) 
 gf 0.8 ζ 9 ∙ 10
-5
 (μΜ-1) 
 n 1.4 β 11.9 (μΜ) 
 d 220 μm f 1 
     δ 33 (μΜ) 
4T1 tumor μa 3.89 cm
-1
 0.94 cm
-1
 0.76 cm
-1
 0g  0.7 (μΜ
 
s
-1
) 
c
 
 μs 68.5 cm
-1
 86.2 cm
-1
 98.0 cm
-1
 [
3
O2]0 60 (μΜ) 
 gf 0.9 [
1
O2]rx,0 
d
 0 
 n 1.54 [S0]corrected 
e 
655 (μΜ) 
 d 1 cm [
1
O2]rx,sh 500 (μΜ) 
     
PpIX μa 1.88 cm
-1
 0.06 cm
-1
 0.0 cm
-1
   
 μs 115.0 cm
-1
 66.7 cm
-1
 66.7 cm
-1
   
 gf 0.9   
 n 1.38   
     
Parietal 
peritoneum 
muscle tissue 
μa 3.0 cm
-1
 2.2 cm
-1
 2.2 cm
-1
   
μs 36.4 cm
-1
 20.5 cm
-1
 19.6 cm
-1
   
gf 0.8   
n 1.4   
a gf, n and d values apply for all wavelenght values of each layer. 
b Obtained from Ref. [10,36]. 
c Obtained from Ref. [7]. 
d Initial concentration of singlet oxygen leading to cell death. 
e PS concentration finally absorbed (after correction factors). 
 
 
2.4 Animals and tumors 
For the preliminary in vivo part of the study 
twelve-week-old female NOD-SCID mice (n = 4) 
were acquired from the Experimental Animal Colony 
of the Institute of Biosciences & Applications of 
National Center for Scientific Research 
―Demokritos‖. They were housed two per cage and 
were maintained and treated according to the EU 
guidelines and ethics. The average mouse weight at 
the PDT day was 22.37 g, measured with a digital 
balance (440-33N, KERN & SOHN GmbH, Balingen, 
Germany). The animals were sacrificed at day 12, 
when the control mouse spontaneously died, by 
putting them in an airtight chamber filled with Iso-Vet 
(Isoflurane 1000 mg/g Inhalation vapor). 
Breast carcinoma 4T1 cells were obtained by 
National Center for Scientific Research 
―Demokritos‖. They were prepared in a 0.25 mL 
suspension containing 1∙106 cells that was inoculated 
subcutaneously in the left flank of each mouse. The 
tumors were allowed to grow until their diameters 
reached approximately 1 cm. 
 
2.5 Fluorescence and temperature imaging 
The fluorescence spectrum of the treated area was 
acquired (i) before the PS application, (ii) just before 
the PDT and (iii) immediately after the treatment 
procedure. A 405 nm (8 mW) LED source was used 
as excitation source (M405FP1, Thorlabs, Germany), 
since the maximum of the PpIX’s Soret band is 
located at 405 nm. The light was collected by a 600 
μm core optical fiber (QP600-2-SR-BX, Ocean 
Optics), attached to a spectrometer (USB 4000, Ocean 
Optics). A 600 nm longpass filter (FEL0600, 
Thorlabs, Germany) was used to eliminate the 405 nm 
light along with unwanted spectrum areas. The 
collected spectrum was processed using SpectraSuite 
software (Ocean Optics), with integration time set at 
100 ms and the background signal was subtracted.
G. Kareliotis et al. 
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Figure 1. The experimental setup used: (a) Schematic representation of the main parts. (b) The optical fiber with the 
metallic housing (on the left of the image) guided the 660 nm beam. The one in the middle (above mouse) guided the 625 
nm or the 405 nm beam (depending on protocol). At the right of the image the collection optical fiber and the longpass 
filter, which were placed as close as possible to the mouse during fluorescence measurements, can be seen. 
 
 
Surface temperature measurements of the mice’s 
abdomen and their left flank were conducted using a 
thermal camera (ToughCam EL S, Infrared Cameras 
Inc.). The setup is presented in Figure 1. 
 
2.6 Treatment procedure 
The hair at the tumor area was carefully shaved the 
day before treatment. Just before applying the PS, 
each mouse was weighed and the fluorescence 
spectrum of the target area was acquired. A thin layer 
(approximately 1 mm thick) of PS, corresponding to 
~30 mg was applied topically at the left flank of each 
mouse, in excess of the visible tumor area, in order to 
cover a 1.5 mm margin. The area was covered with 
Parafilm (PM 996) which was attached by surgical 
tape (Micropore™, 3M™) and then the mouse was 
kept for 3h in its cage. Cages were covered with black 
fabric to prevent unwanted photosensitization. 
Afterwards, the mouse was intraperitoneally injected 
with a solution of ketamine/xylazine (hydrochloric 
ketamine 100 mg/mL, 10% and hydrochloric xylazine 
23.32 mg/mL, 5%), at 10 mg/kg of body weight. 
The cancerous area was irradiated using a 625 nm 
LED (M625F2, Thorlabs, Germany) (mouse No. 1) 
and a 660 nm diode laser (PSU-III, CNI 
Optoelectronics Tech. Co., China) (mouse No. 2). 
One mouse (mouse No. 3) was subjected to combined 
therapy, with both light sources illuminating it 
simultaneously, in a 50-50 light dose separation. The 
light sources’ power values (P) were obtained using a 
power meter (PM100A, Thorlabs, Germany) with a Si 
Photodiode detector (S121C, Thorlabs, Germany). 
 
2.7 Data analysis 
Treatment evaluation was performed by 
examination of the growth curves of the PDT treated 
and the control mice. The measurements were 
conducted by setting the jaws of a caliper (with 0.01 
mm accuracy) around the largest and smallest tumor 
diameters observed. The tumor area and the tumor 
volume were estimated using Equations 5 and 6, 
respectively. 
       
                        
 
         ( ) 
       
                       
  
 
        ( ) 
At day twelve after treatment the mice were 
sacrificed, the tumors were extracted and their masses 
were recorded. 
 
3 Results 
The computational simulation revealed the 
differences arising from the penetration depth of each 
light source. As it can be seen from Figures 2(b-d), 
longer wavelengths offer higher fluence rates in 
deeper planes; and as a result deeper lying tissue is 
able to absorb significant higher amounts of energy 
(see Fig. 2(b) and (f)). The skin and tumor μs values 
were accounted to be responsible for the increased φ 
values recorded on the upper layers of the model, 
where transmmited and scattered photons coexist. In 
the 660 nm light case φ exceeded superficially the 
thershold of 200 mW∙cm-2 in order to achieve high 
enough values inside the tumor volume.  
The variations of cytotoxic produced molecules at 
the end of PDT irradiation are presented in Figure 
3(a). The highest [
1
O2]rx was recorded for the 625 nm 
light protocol and the lowest for the 660 nm one. 
Although the total radiant exposure was in all cases 
the same (approximately 100 J∙cm-2), the [1O2]rx 
fluctuated by more than a threefold.  
The combined light sources protocol applied to 
mouse No. 3 resulted in intermediate [
1
O2]rx values. 
One case scenario was implemented in Figure 3(b), 
where two equal irradiation time values were applied
G. Kareliotis et al. 
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Figure 2. (a) Planar view of the simulated model, where the vertical red lines represent the beam’s path. (b) Spatial profile 
of fluence rate versus depth for the fluorescence and irradiation beams, for the first 1.2 cm. (c, d) Spatial profiles of beam 
fluence rate and (e, f) energy deposition versus depth for the irradiation beams. 
 
 
for the two different light sources. Despite the lower 
penetration depth of the 625 nm beam, its higher, 
compared to the other beam’s, absorption coefficient 
resulted in ~50% increased (
1
O2)rx production at the 
first 0.5 cm of the tumor (for irradiation time of 820 
s). On the contrary, beyond that point, the higher 
penetration depth and fluence rate of the 660 nm 
beam begun to compensate for its lower μa value. 
Moreover, the increased irradiation time (1650 s) with 
the 660 nm light produced the same amount of (
1
O2)rx, 
denoting a possible treatment saturation, as far as the 
specific parameters’ values are concerned. Another 
case scenario, presented in Figure 3(c), studied three 
possible combinations of light sources, in order to 
achieve total radiant exposure of ~100 J∙cm-2. The 
75% - 25% split of 625 nm – 660 nm beams resulted 
in 3% higher [
1
O2]rx values than those of irradiation 
with 625 nm only, while treatment time was reduced 
in half. The corresponding increase for the reverse 
protocol (25% - 75%) and the sole use of 660 nm was 
19%. The graph was deliberately not incorporated 
into Figure 3(a) for clarity reasons. Finally, Figure 
3(d) presents the irradiation time needed for the 
protocols of Figures 3(a, c). 
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Figure 3. (a) Comparison of the [
1
O2]rx produced by irradiation with 625 nm, 600 nm and their combination, for H ≈ 100 
J∙cm-2. (b) Effect of irradiation time on [1O2]rx produced for 625 nm and 660 nm. (c) The effect on [
1
O2]rx of three different 
combinations of the light sources, in terms of percentage contribution on total radiant exposure of ~100 J∙cm-2. The 50% - 
50% case corresponds to the irradiation conditions of mouse No. 3. (d) Irradiation time needed for protocols of (a) and (c). 
 
 
The fluorescence spectrum of each mouse was 
collected after the 3h period of PS uptake, the tumor 
area wash with sodium chloride and just before 
irradiation. As shown in Figure 4(a) the mouse that 
was to be irradiated with the 660 nm source presented 
the lowest intensity signal, while the peak 
fluorescence of the other two mice (No. 1 and No. 3) 
was at similar levels. The main three peaks were 
observed at 604, 636 and 704 nm with minimum 
variations. Figure 4(b) presents the acquired 
fluorescence spectra of the mice No. 2 and No. 3 right 
after PDT. The corresponding spectrum of mouse No. 
1 is not shown as the data were corrupted. Figure 4(c) 
is indicative of the differences in the fluorescence 
spectra of an untreated area, an area with accumulated 
PpIX molecules and the same area after PDT (with 
dotted blue, continuous red and dashed green lines, 
respectively; as shown in the online colored version). 
The pre-PS administration curve presented topical 
maxima at 604, 622, 750 and 774 nm. After the PS 
administration the topical maxima were located at 
604, 636 and 704 nm, for both pre- and post-
irradiation. The main difference between the two 
latter was the fluorescence intensity, which was more 
than a twofold for the pre-irradiation case, regarding 
the main maximum wavelength observed (636 nm). 
Area and volume measurements of the tumor region 
are presented in Figures 5(a) and (b). The percentage 
tumor growth is higher after PDT with the 
combination of 625 and 660 nm light than that of 625 
nm and the 660 nm light alone. Interestingly, the 
tumor of the control mouse showed the lowest 
increase rate. 
Temperature measurements of the mice’s tumors 
and the abdomens were conducted throughout the 
experiment. As shown in Figure 5(d), the tumor area 
presented higher values than healthy tissue, although 
as days were passing by this difference tended to 
minimize. The temperature of the control mouse and 
the one treated with the combination of light sources 
(mice No. 4 and No. 3, respectively) was the highest 
observed (37.3 and 39.3
o
C, respectively) at day 7. As 
far as the mouse No. 2 is concerned, it constantly 
presented lower temperature values than the others.
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Figure 4. Fluorescence spectra of the areas to be treated just before (a) and right after (b) irradiation with each light source 
(the spectrum corresponding to the 625 nm right after irradiation was corrupted and is not shown). (c) Fluorescence spectra 
of the treated area: before photosensitizer application (dotted line), just before (continuous line) and right after PDT 
treatment (dashed line) with both 625 and 660 nm light sources. 
 
 
 
Figure 5. Tumor growth expressed as change (%) of (a) area at the middle of the tumor and (b) volume, for each PDT 
scheme. (c) Tumor temperature throughout protocol and (d) temperature variation between tumor and abdomen. 
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Figure 6. (a) Tumor size measurement and (b) the extracted tumors of the 3 PDT treated mice (numbered sequentially) and 
of the control mouse (denoted as ―C‖). 
 
 
Day 12 was considered to be the end of the 
experiment since the control mouse spontaneously 
died; and therefore the rest of the animals were 
euthanized, and the tumors were extracted and 
weighed. At that day, mouse No. 1 had to be 
subjected to resuscitational procedures, with its 
temperature being significantly lower than that of the 
two alive mice (see Fig. 5(c)). At that timepoint the 
tumors had begun to infiltrate the leg area and also to 
cover the humerus, while they were consistent in 
texture and color (see Fig. 6). The tumor mass values 
presented small variations, with the lighter tumor 
being the one treated with the combination light 
sources protocol (4.26 ± 0.01 g). Nevertheless, the 
same value applied also for the tumor of the control 
mouse. The heavier tumor was that of mouse No. 2 
(5.32 ± 0.01 g), while the one of mouse No. 1 
weighed 4.69 ± 0.01 g. 
 
4 Discussion 
In this study Metvix was selected as the 
photosensitizing agent. It is an affordable, easy to use 
PS media that does not need to be intravenously 
injected and therefore presents fewer side effects for 
the animals. Although the drug’s therapeutic 
indications are focused on the treatment of cancer 
cases such as actinic keratosis (AK), superficial and 
nodular basal cell carcinoma (BCC) and squamous 
cell carcinoma (Bowen´s disease) [18], published 
studies have also examined its use in mammary 
adenocarcinoma cells (MDA–MB–231 cells) [16] but 
to the best of our knowledge, none for the treatment 
of 4T1 tumors. 
The importance of appropiate wavelength 
selection and irradiation time in (
1
O2)rx production 
and hence, in treatment outcome is denoted in Figure 
2. Both 625 nm and 660 nm are within the range of 
excitation wavelengths proposed by the PS 
manifacturer [18] but with different efficacy and φ 
values. Although the 625 nm light has lower 
penetration depth than 660 nm, the corresponding 
[
1
O2]rx was significantly higher, especially in the first 
tumor’s millimeters. This was attributed to two main 
factors; even though the total radiant exposure was 
the same in all mice. Firstly, to the higher value of 
PpIX’s μa at 625 nm than at 660 nm, and secondly, to 
the more than a threefold longer irradiation time 
between the mouse treated with 625 nm and the one 
treated with 660 nm, allowing the tumor’s periphery 
reoxygenation (the reader should bear in mind that its 
core is hypoxic [38]). The lowest cytotoxic oxygen 
production was observed for the 660 nm irradiation, 
where the corresponding [
1
O2]rx was lower than 500 
μΜ. The mouse treated with that protocol presented 
also the lowest tumor temperature (see Fig. 5(c)) and 
the heaviest extracted tumor. As it can be deducted 
from the results of the computational simulations 
presented in Figure 3, the lower absorption of 660nm 
could be compensated by increased irratiation time, 
although this presupposes prolonged anesthesia time. 
In clinical practice this could be unconvinient for the 
patient (PDT induces skin burning sensation) but also 
time and money consuming for the clinic. At this 
point, it has to be noted that increased treatment times 
do not necessarily lead to increased [
1
O2]rx values, as 
the amount of available PS is not infinite (see Fig. 
3(b)) and hence, is going to affect PDT efficacy. 
Additionally, the accumulating photobleached PS 
molecules act as a barrier for penetrating light, 
reducing further (
1
O2)rx production. Therefore, an 
effective combination of 625 nm and 660 nm light 
should be able to enhance the therapeutic outcome 
(see Fig. 3(c)). The PDT part with the 625 nm light 
takes advantage of the higher μa value, while the 660 
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nm part allows treatment of deeper tumor layers (see 
Fig. 3(d)). The combination light sources protocol 
was further supported by the in vivo results, since the 
corresponding mouse had the lowest extracted 
tumor’s mass, even though it presented the highest 
rate of tumor area and volume increase (see Fig. 5(a) 
and (b)). Moreover, this mouse presented low tumor 
and body temperature variations throughout 
experiment. 
Fluorescence spectroscopy plays significant role in 
non-invasive cancer diagnosis but also in 
quantification of photosensitizer’s concentration. As it 
is well known, the main cytotoxic product in MAL-
PDT is PpIX and hence, its detection is widely used 
in relevant studies [39,40]. The fluorescence spectra 
collected just before PDT treatment (see Fig. 4(a)) are 
consistent with the PpIX fluorescence spectrum found 
in literature [41,42]. They include the main peaks of 
~635 and ~705 nm, making a rough correlation 
between fluorescence intensity and PS concentration 
possible. The almost half maximum intensity value 
recorded from mouse No. 2 should not be considered 
as an absolute value but rather as a quality result; 
since the tip of the collection fiber was further from 
the skin than at the rest of the setups, due to technical 
reasons. On the other hand, that mouse presented the 
heaviest extracted tumor, denoting a reasonable and 
expected correlation between the PpIX concentration 
and therapeutic outcome. The latter is also supported 
by the increased post-PDT PpIX fluorescence of 
mouse No. 2, showing its decreased photobleaching 
and hence, the lower (
1
O2)rx production. 
Unfortunately, the relevant post-PDT data of mouse 
No. 3 were not available, as the setup was 
accidentally violently moved. The PDT outcome is 
highly correlated to the presence of PpIX, whose 
concentration fluctuates during treatment. The reader 
should have in mind that it is produced by MAL 
conversion but at the same time it is photobleached 
and biologically removed and hence, its absorption 
coefficient changes during PDT [43]. Moreover, the 
cell density also affects treatment’s efficiency, 
through the cellular PpIX distribution [44]. 
The in vivo study was in agreement with the 
computational model, as the treatment delayed the 
tumor growth in a manner in agreement with literature 
[16]. A comparison of the preliminary in vivo results 
with that of Sutoris et al. [16] reveals the same 
behavior of the tumor volume, i.e. a slight increase 
(day 1) followed by a volume decrease and tumor 
regrowth. The different time scale (faster in our case) 
is possibly attributed to the higher aggressiveness of 
the 4T1 cells used compared to the mammary 
adenocarcinoma cells of the Sutoris et al. study; and 
to the limited action of superficially applied 
photosensitizing agents. The control mouse received 
PS but no light and hence, no effect on tumor growth 
was expected [16]. It should be noted that the 405 nm 
light used for fluorescence measurements was not 
able to induce any PDT anti-tumor effects, due to its 
low penetration depth (see Fig. 2(b)) and its low 
fluence rate. The fact that the area, volume and mass 
measurements showed no significant tumor size 
differences between the control and the treated mice 
cannot be evaluated in a statistically significant 
manner, due to the small mice sample. Nevertheless, 
studies with similar results do exist in literature 
[26,29], basing their observations mainly on the high 
blood vessel compression and the hypoxic conditions 
within the 4T1 tumor. In addition and according to 
the in silico part of the study, the main necrotic area 
was expected to be on the upper part of tumor 
volume, considering the superficial irradiation setup. 
Therefore, the minimum treatment impact to the 
tumor’s periphery (that was mechanically measured) 
did not come as a surprise. On the contrary, the fact 
that the untreated mouse died, while most of the rest 
did not present deteriorated clinical status can account 
as a successful treatment outcome. 
The mechanically obtained measurements of the 
maximum and the minimum tumor diameters were 
based on Equation 6, which is widely used in 
literature to estimate tumor volume [16,45]. In this 
experiment though, the PS and the light delivery were 
applied from the skin overlaying on the tumor, 
making the treatment more superficial than whole-
tumor based, and thus not uniform, and the use of 
Equation 6 not ideal. In order to improve our 
estimations, the middle horizontal plane area was 
calculated using Equation 5. As the results showed, 
the latter way seems to be more precise for this type 
of therapy, since it presented lower divergence than 
the former as far as the tumor mass is also concerned. 
Nevertheless, the extracted tumor mass measurements 
revealed that even more accurate and sophisticated 
imaging methods are needed for this kind of study 
(e.g. magnetic resonance imaging – MRI), as the best 
treatment outcome (the one of mouse No. 3) 
presented the highest tumor growth rate, and the 
worst (the one of mouse No. 4 that died first) the 
lowest tumor growth rate. 
The in vivo protocol of this study also included 
regular temperature measurements of both the tumor 
and the body (abdomen) of the mice before and after 
PDT. Unfortunately, the literature is poor in relevant 
post-PDT data since most published studies focus on 
the photothermal effects during and not after therapy 
and hence, a comparison with our results was not 
possible [46,47]. Nevertheless, temperature 
monitoring is a high value procedure as it can reflect 
the mouse’s condition in a rapid and non-invasive 
manner [48,49]. Furthermore, temperature 
heterogeneities are expected between the tumor and 
adjacent tissue, since tumors present abnormal 
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perfusion and metabolic rates [50]. This fact was also 
observed in the present study where the tumor 
temperature presented higher values than its 
surrounding area, in accordance with other 4T1 
studies in literature [51,52], probably attributed to 
local inflammatory response [53]. At sacrifice day, 
the temperature of mouse No. 1 was approximately 
50% lower than the one of mice No. 2 and No. 3, 
attributed to decreased metabolic rhythms that 
possibly denoted a decline in its vital functions [54]. 
The decreasing temperature difference between 
healthy and tumorous tissue following treatment was 
attributed to the vascular shutdown, as the limited 
blood perfusion into the tumor lead to lower thermal 
loads. 
Conventional ways to increase the PDT 
therapeutic outcome include the selection of PSs with 
high absorption at the wavelength used, as well as 
increased [S0] and irradiation time. However, toxicity, 
pain, time and cost issues are raised. Moreover, most 
approved and clinically available PSs present 
absorption maxima below the infrared (IR) part of the 
electromagnetic spectrum, where penetration depth is 
limited. Consequently, the need of alternative 
methods to enhance PDT efficacy leads to application 
of novel modalities. Nanoparticles (NPs) can play a 
crucial role in drug delivery and selectivity [55]. A 
specific NP type, namely upconversion NPs, has the 
ability to emit light of shorter wavelength than the 
one used for its irradiation [56]. Hence, deep 
penetrating beams (i.e. IR light) can be used to 
indirectly excite photosensitizing agents that have 
much lower excitation bands. The combination of 
treatment modalities also shows upscaled therapeutic 
outcome. The synergistic effects of radiotherapy and 
proton therapy schemes along with PDT offer 
promising results and an emerging research field 
[57,58]. Other, less sophisticated ways to enhance 
tumor response do exist, as for instance 
administration of low vitamin D doses [59]. 
Additionally, housing temperature has also been 
correlated to treatment outcome, as cold-stress can 
activate physiological changes that affect tumor 
growth [60]. 
 
5 Conclusions 
This in silico study, accompanied by some 
preliminary in vivo results, presented the impact that 
different light protocols have on PDT of 4T1 tumors. 
The optical properties of the photosensitizing agent 
along with the irradiation parameters strongly affect 
the therapeutic outcome. Moreover, the conventional 
equations for tumor volume estimation seem to be 
insufficient, when PSs are superficially applied. The 
simultaneous acquisition of fluorescence data, in 
addition to temperature measurements are seen to 
assist the treatment prognosis. Computational 
simulations, although with some assumptions, are 
supported by the fluorescence and temperature data 
that show decreased treatment effect when using light 
with a mismatch to the maximum excitation 
wavelength of the PS, even if high fluence rates are 
used. The choice of appropriate excitation light that 
matches the absorption coefficient of the PS is crucial 
but presents limitations if it has low penetration 
depth. In this study’s case, the best results arose from 
the appropriate combination of light sources (75% - 
25% split of 625 nm – 660 nm beams) that seems to 
be more sufficient than solely manipulating treatment 
parameters, such as irradiation time. As a result, we 
strongly believe that this protocol deserves further 
investigation, as it has the potential to attribute to the 
enhancement of therapeutic outcome. 
 
Acknowledgements 
We gratefully acknowledge the donation of Metvix 
cream by Pharmaserve – Lilly S.A.C.I. (Kifisia, 
Greece) for the needs of this study. The author’s G.K. 
research has been co-financed by Greece and the 
European Union (European Social Fund- ESF) 
through the Operational Program «Human Resources 
Development, Education and Lifelong Learning» in 
the context of the project ―Strengthening Human 
Resources Research Potential via Doctorate 
Research‖ (MIS-5000432), implemented by the State 
Scholarships Foundation (ΙΚΥ) [Scholarship number: 
2018-050-0502-14578]. The authors E.D. and M.M. 
gratefully acknowledge the funding of the European 
Regional Development Fund (ERDF) and National 
Funds ―Synergy ELI-LASERLAB EUROPE, HiPER 
& IPERION-CH.gr (MIS 5002735)‖, 2017. The 
donating and funding sources had no involvement in 
the study design; in the collection, analysis and 
interpretation of data; in the writing of the report; and 
in the decision to submit the article for publication. 
 
 
References 
 
[1] T.J. Dougherty, J.E. Kaufman, A. Goldfarb, K.R. 
Weishaupt, D. Boyle, A. Mittleman, Photoradiation 
therapy for the treatment of malignant tumors, Cancer 
Res. 38 (1978) 2628–2635. 
[2] J. Soriano, I. Mora-Espí, M.E. Alea-Reyes, L. Pérez-
García, L. Barrios, E. Ibáñez, C. Nogués, Cell death 
mechanisms in tumoral and non-tumoral human cell 
lines Triggered by photodynamic treatments: 
apoptosis, necrosis and parthanatos, Sci. Rep. 7 
(2017) 41340. https://doi.org/10.1038/srep41340. 
G. Kareliotis et al. 
12 
 
[3] S. Nath, G. Obaid, T. Hasan, The course of immune 
stimulation by photodynamic therapy: bridging 
fundamentals of photochemically induced 
immunogenic cell death to the enrichment of T-cell 
repertoire, Photochem. Photobiol. 95 (2019) 1288–
1305. https://doi.org/10.1111/php.13173. 
[4] M. Wachowska, A. Muchowicz, M. Firczuk, M. 
Gabrysiak, M. Winiarska, M. Wańczyk, K. 
Bojarczuk, J. Golab, Aminolevulinic acid (ALA) as a 
prodrug in photodynamic therapy of cancer, 
Molecules. 16 (2011) 4140–4164. 
https://doi.org/10.3390/molecules16054140. 
[5] H. Wu, T. Minamide, T. Yano, Role of photodynamic 
therapy in the treatment of esophageal cancer, Dig. 
Endosc. 31 (2019) 508–516. 
https://doi.org/10.1111/den.13353. 
[6] B. Liu, T.J. Farrell, M.S. Patterson, Comparison of 
photodynamic therapy with different excitation 
wavelengths using a dynamic model of 
aminolevulinic acid-photodynamic therapy of human 
skin, J Biomed Opt. 17 (2012) 88001. 
https://doi.org/10.1117/1.jbo.17.8.088001. 
[7] K.K. Wang, J.C. Finlay, T.M. Busch, S.M. Hahn, 
T.C. Zhu, Explicit dosimetry for photodynamic 
therapy: macroscopic singlet oxygen modeling, J 
Biophotonics. 3 (2010) 304–318. 
https://doi.org/10.1002/jbio.200900101. 
[8] T.C. Zhu, M.M. Kim, X. Liang, J.C. Finlay, T.M. 
Busch, In-vivo singlet oxygen threshold doses for 
PDT, Photonics Lasers Med. 4 (2015) 59–71. 
https://doi.org/10.1515/plm-2014-0037. 
[9] H.S. de Bruijn, S. Brooks, A. van der Ploeg-van den 
Heuvel, T.L.M. ten Hagen, E.R.M. de Haas, D.J. 
Robinson, Light fractionation significantly increases 
the efficacy of photodynamic therapy using BF-200 
ALA in normal mouse skin, PLoS One. 11 (2016) 
e0148850. 
https://doi.org/10.1371/journal.pone.0148850. 
[10] M.M. Kim, A.A. Ghogare, A. Greer, T.C. Zhu, On the 
in vivo photochemical rate parameters for PDT 
reactive oxygen species modeling, Phys Med Biol. 62 
(2017) R1-r48. 
https://doi.org/https://doi.org/10.1088/1361-
6560/62/5/r1. 
[11] B.A. Pulaski, S. Ostrand-Rosenberg, Reduction of 
established spontaneous mammary carcinoma 
metastases following immunotherapy with major 
histocompatibility complex class II and B7.1 cell-
based tumor vaccines, Cancer Res. 58 (1998) 1486–
1493. 
[12] C.P. Wild, E. Weiderpass, B.W. Stewart, eds., World 
Cancer Report: Cancer Research for Cancer 
Prevention, International Agency for Research on 
Cancer (IARC), Lyon, 2020. 
https://doi.org/10.1016/j.cma.2010.02.010. 
[13] V.P. Baklaushev, N.F. Grinenko, G.M. Yusubalieva, 
M.A. Abakumov, I.L. Gubskii, S.A. Cherepanov, I.A. 
Kashparov, M.S. Burenkov, E.Z. Rabinovich, N. V 
Ivanova, O.M. Antonova, V.P. Chekhonin, Modeling 
and integral X-ray, optical, and MRI visualization of 
multiorgan metastases of orthotopic 4T1 breast 
carcinoma in BALB/c mice, Bull Exp Biol Med. 158 
(2015) 581–588. https://doi.org/10.1007/s10517-015-
2810-3. 
[14] H.S. Lee, A.W. Ha, W.K. Kim, Effect of resveratrol 
on the metastasis of 4T1 mouse breast cancer cells in 
vitro and in vivo, Nutr. Res. Pract. 6 (2012) 294–300. 
https://doi.org/10.4162/nrp.2012.6.4.294. 
[15] Y. Xie, Z.B. Wei, Z. Zhang, W. Wen, G.W. Huang, 
Effect of 5-ALA-PDT on VEGF and PCNA 
expression in human NPC-bearing nude mice, Oncol 
Rep. 22 (2009) 1365–1371. 
[16] K. Sutoris, D. Vetvicka, L. Horak, J. Benes, M. 
Nekvasil, P. Jezek, M. Zadinova, P. Pouckova, 
Evaluation of topical photodynamic therapy of 
mammary carcinoma with an experimental gel 
containing liposomal hydroxyl-aluminium 
phthalocyanine, Anticancer Res. 32 (2012) 3769–
3774. 
[17] X. Wang, J. Hu, P. Wang, S. Zhang, Y. Liu, W. 
Xiong, Q. Liu, Analysis of the in vivo and in vitro 
effects of photodynamic therapy on breast cancer by 
using a sensitizer, sinoporphyrin sodium, 
Theranostics. 5 (2015) 772–786. 
https://doi.org/10.7150/thno.10853. 
[18] Metvix 160 mg/g cream, (n.d.). 
https://www.medicines.org.uk/emc/product/6777/smp
c (accessed March 25, 2020). 
[19] S.H. Choi, K.H. Kim, K.-H. Song, Efficacy of 
ablative fractional laser-assisted photodynamic 
therapy for the treatment of actinic cheilitis: 12-month 
follow-up results of a prospective, randomized, 
comparative trial., Br. J. Dermatol. 173 (2015) 184–
191. https://doi.org/10.1111/bjd.13542. 
[20] A.E. O’Connor, W.M. Gallagher, A.T. Byrne, 
Porphyrin and nonporphyrin photosensitizers in 
oncology: preclinical and clinical advances in 
photodynamic therapy, Photochem. Photobiol. 85 
(2009) 1053–1074. https://doi.org/10.1111/j.1751-
1097.2009.00585.x. 
[21] G. Kareliotis, M. Papachristou, D. Priftakis, I. 
Datseris, M. Makropoulou, Computational study of 
necrotic areas in rat liver tissue treated with 
photodynamic therapy, J Photochem Photobiol B. 192 
(2019) 40–48. 
https://doi.org/https://doi.org/10.1016/j.jphotobiol.201
9.01.007. 
[22] G. Kareliotis, S. Liossi, M. Makropoulou, Assessment 
of singlet oxygen dosimetry concepts in 
photodynamic therapy through computational 
modeling, Photodiagnosis Photodyn. Ther. 21 (2018). 
https://doi.org/10.1016/j.pdpdt.2017.12.016. 
[23] K. Calabro, A. Curtis, J.-R. Galarneau, T. Krucker, 
I.J. Bigio, Gender variations in the optical properties 
of skin in murine animal models, J. Biomed. Opt. 16 
(2011) 11008. https://doi.org/10.1117/1.3525565. 
[24] S. Tabassum, V. Pera, G. Greening, T.J. Muldoon, D. 
Roblyer, Two-layer inverse model for improved 
longitudinal preclinical tumor imaging in the spatial 
frequency domain, J. Biomed. Opt. 23 (2018) 1–12. 
https://doi.org/10.1117/1.JBO.23.7.076011. 
[25] U. Sunar, D.J. Rohrbach, J. Morgan, N. Zeitouni, 
B.W. Henderson, Quantification of PpIX 
concentration in basal cell carcinoma and squamous 
G. Kareliotis et al. 
13 
 
cell  carcinoma models using spatial frequency 
domain imaging., Biomed. Opt. Express. 4 (2013) 
531–537. https://doi.org/10.1364/BOE.4.000531. 
[26] K. Vishwanath, H. Yuan, W.T. Barry, M.W. 
Dewhirst, N. Ramanujam, Using optical spectroscopy 
to longitudinally monitor physiological changes 
within solid tumors, Neoplasia. 11 (2009) 889–900. 
https://doi.org/10.1593/neo.09580. 
[27] A.N. Bashkatov, K. V Berezin, K.N. Dvoretskiy, 
M.L. Chernavina, E.A. Genina, V.D. Genin, V.I. 
Kochubey, E.N. Lazareva, A.B. Pravdin, M.E. 
Shvachkina, P.A. Timoshina, D.K. Tuchina, D.D. 
Yakovlev, D.A. Yakovlev, I.Y. Yanina, O.S. 
Zhernovaya, V. V Tuchin, Measurement of tissue 
optical properties in the context of tissue optical 
clearing, J. Biomed. Opt. 23 (2018) 1–31. 
https://doi.org/10.1117/1.JBO.23.9.091416. 
[28] S.L. Jacques, Optical properties of biological tissues: 
a review, Phys. Med. Biol. 58 (2013) R37-61. 
https://doi.org/10.1088/0031-9155/58/11/R37. 
[29] G. Ramirez, A.R. Proctor, K.W. Jung, T.T. Wu, S. 
Han, R.R. Adams, J. Ren, D.K. Byun, K.S. Madden, 
E.B. Brown, T.H. Foster, P. Farzam, T. Durduran, R. 
Choe, Chemotherapeutic drug-specific alteration of 
microvascular blood flow in murine  breast cancer as 
measured by diffuse correlation spectroscopy., 
Biomed. Opt. Express. 7 (2016) 3610–3630. 
https://doi.org/10.1364/BOE.7.003610. 
[30] N. Rajaram, A.F. Reesor, C.S. Mulvey, A.E. Frees, N. 
Ramanujam, Non-invasive, simultaneous 
quantification of vascular oxygenation and glucose 
uptake in tissue, PLoS One. 10 (2015) e0117132–
e0117132. 
https://doi.org/10.1371/journal.pone.0117132. 
[31] C.P. Sabino, A.M. Deana, T.M. Yoshimura, D.F.T. da 
Silva, C.M. França, M.R. Hamblin, M.S. Ribeiro, The 
optical properties of mouse skin in the visible and 
near infrared spectral regions, J. Photochem. 
Photobiol. B. 160 (2016) 72–78. 
https://doi.org/10.1016/j.jphotobiol.2016.03.047. 
[32] C.L. Campbell, C.T.A. Brown, K. Wood, H. Moseley, 
Modelling topical photodynamic therapy treatment 
including the continuous production of 
Protoporphyrin IX, Phys. Med. Biol. 61 (2016) 7507–
7521. https://doi.org/10.1088/0031-9155/61/21/7507. 
[33] E. Beaulieu, A. Laurence, M. Birlea, G. Sheehy, L. 
Angulo-Rodriguez, M. Latour, R. Albadine, F. Saad, 
D. Trudel, F. Leblond, Wide-field optical 
spectroscopy system integrating reflectance and 
spatial frequency domain imaging to measure 
attenuation-corrected intrinsic tissue fluorescence in 
radical prostatectomy specimens, Biomed. Opt. 
Express. 11 (2020) 2052–2072. 
https://doi.org/10.1364/BOE.388482. 
[34] C. Dupont, S. Mordon, P. Deleporte, N. Reyns, M. 
Vermandel, A novel device for intraoperative 
photodynamic therapy dedicated to glioblastoma  
treatment., Future Oncol. 13 (2017) 2441–2454. 
https://doi.org/10.2217/fon-2017-0261. 
[35] S. Wiegell, Update on photodynamic treatment for 
acrinic keratosis, in: P. Soyer, T. Prow, G. Jemec 
(Eds.), Actinic Keratosis, Karger, Basel, 2015: pp. 
122–128. 
https://books.google.gr/books?id=EbFoBgAAQBAJ&
pg=PA10&lpg=PA10&dq=metvix+is+demethylated+
to+ALA+PpIX&source=bl&ots=wWqtKr67wL&sig=
ACfU3U3e6ylkHsr0ryy3a3DIYQeXnmPZwA&hl=en
&sa=X&ved=2ahUKEwj0h8-
mz4XoAhWRoXEKHTjNDcUQ6AEwBXoECBAQ
AQ#v=onepage&q=metvix is demet (accessed March 
6, 2020). 
[36] T.C. Zhu, B. Liu, M.M. Kim, D. McMillan, X. Liang, 
J.C. Finlay, T.M. Busch, Comparison of singlet 
oxygen threshold dose for PDT, Proc SPIE Int Soc 
Opt Eng. 8931 (2014). 
https://doi.org/10.1117/12.2039719. 
[37] METVIX - Product Monograph, (2017). 
https://www.galderma.com/sites/g/files/jcdfhc196/file
s/inline-files/Metvix-PM-E.pdf (accessed March 25, 
2020). 
[38] G. Kareliotis, I. Tremi, M. Kaitatzi, E. Drakaki, A.A. 
Serafetinides, M. Makropoulou, A.G. Georgakilas, 
Combined radiation strategies for novel and enhanced 
cancer treatment, Int. J. Radiat. Biol. (2020) 1–55. 
https://doi.org/10.1080/09553002.2020.1787544. 
[39] Y. Kitajima, T. Ishii, T. Kohda, M. Ishizuka, K. 
Yamazaki, Y. Nishimura, T. Tanaka, S. Dan, M. 
Nakajima, Mechanistic study of PpIX accumulation 
using the JFCR39 cell panel revealed a role for 
dynamin 2-mediated exocytosis, Sci. Rep. 9 (2019) 
8666. https://doi.org/10.1038/s41598-019-44981-y. 
[40] T. Osaki, I. Yokoe, Y. Sunden, U. Ota, T. Ichikawa, 
H. Imazato, T. Ishii, K. Takahashi, M. Ishizuka, T. 
Tanaka, L. Li, M. Yamashita, Y. Murahata, T. Tsuka, 
K. Azuma, N. Ito, T. Imagawa, Y. Okamoto, Efficacy 
of 5-aminolevulinic acid in photodynamic detection 
and photodynamic therapy in veterinary medicine, 
Cancers (Basel). 11 (2019) 495. 
https://doi.org/10.3390/cancers11040495. 
[41] N.A. Markwardt, N. Haj-Hosseini, B. Hollnburger, H. 
Stepp, P. Zelenkov, A. Rühm, 405 nm versus 633 nm 
for protoporphyrin IX excitation in fluorescence-
guided stereotactic biopsy of brain tumors, J. 
Biophotonics. 9 (2016) 901–912. 
https://doi.org/10.1002/jbio.201500195. 
[42] M. Marois, J. Bravo, S.C. Davis, S.C. Kanick, 
Characterization and standardization of tissue-
simulating protoporphyrin IX optical phantoms, J. 
Biomed. Opt. 21 (2016) 035003. 
https://doi.org/10.1117/1.jbo.21.3.035003. 
[43] A.-S. Vignion-Dewalle, G. Baert, L. Devos, E. 
Thecua, C. Vicentini, L. Mortier, S. Mordon, Red 
light photodynamic therapy for actinic keratosis using 
37 J/cm2: Fractionated irradiation with 12.3 mW/cm2 
after 30 minutes incubation time compared to 
standard continuous irradiation with 75 mW/cm2 after 
3 hours incubation time using a mathematical m, 
Lasers Surg. Med. 49 (2017) 686–697. 
https://doi.org/10.1002/lsm.22665. 
[44] S.L. Gibson, J.J. Havens, M.L. Nguyen, R. Hilf, 
Delta-aminolaevulinic acid-induced photodynamic 
therapy inhibits protoporphyrin IX biosynthesis and 
reduces subsequent treatment efficacy in vitro., Br. J. 
Cancer. 80 (1999) 998–1004. 
G. Kareliotis et al. 
14 
 
https://doi.org/10.1038/sj.bjc.6690454. 
[45] Z.S. Tong, P.T. Miao, T.T. Liu, Y.S. Jia, X.D. Liu, 
Enhanced antitumor effects of BPD-MA-mediated 
photodynamic therapy combined with adriamycin on 
breast cancer in mice, Acta Pharmacol Sin. 33 (2012) 
1319–1324. https://doi.org/10.1038/aps.2012.45. 
[46] E. Austin, E. Koo, J. Jagdeo, Thermal photodynamic 
therapy increases apoptosis and reactive oxygen 
species generation in cutaneous and mucosal 
squamous cell carcinoma cells, Sci. Rep. 8 (2018) 
12599. https://doi.org/10.1038/s41598-018-30908-6. 
[47] Z. Yang, Z. Sun, Y. Ren, X. Chen, W. Zhang, X. Zhu, 
Z. Mao, J. Shen, S. Nie, Advances in nanomaterials 
for use in photothermal and photodynamic 
therapeutics (Review), Mol Med Rep. 20 (2019) 5–
15. https://doi.org/10.3892/mmr.2019.10218. 
[48] C. Song, V. Appleyard, K. Murray, T. Frank, W. 
Sibbett, A. Cuschieri, A. Thompson, Thermographic 
assessment of tumor growth in mouse xenografts, Int. 
J. Cancer. 121 (2007) 1055–1058. 
https://doi.org/10.1002/ijc.22808. 
[49] M. Tepper, A. Shoval, O. Hoffer, H. Confino, M. 
Schmidt, I. Kelson, Y. Keisari, I. Gannot, 
Thermographic investigation of tumor size, and its 
correlation to tumor relative temperature, in mice with 
transplantable solid breast carcinoma, J. Biomed. Opt. 
18 (2013) 1–11. 
https://doi.org/10.1117/1.JBO.18.11.111410. 
[50] M.M. Kim, R. Penjweini, T.C. Zhu, In vivo outcome 
study of BPD-mediated PDT using a macroscopic 
singlet oxygen model, Proc. SPIE--the Int. Soc. Opt. 
Eng. 9308 (2015). 
https://doi.org/10.1117/12.2077803. 
[51] S. Jie, X. Guo, Z. Ouyang, Tumor ablation using 
novel photothermal NaxWO3 nanoparticles against 
breast cancer osteolytic bone metastasis, Int. J. 
Nanomedicine. 14 (2019) 7353–7362. 
https://doi.org/10.2147/IJN.S217974. 
[52] R. Liu, J. Tang, Y. Xu, Y. Zhou, Z. Dai, Nano-sized 
indocyanine green J-aggregate as a one-component 
theranostic agent, Nanotheranostics. 1 (2017) 430–
439. https://doi.org/10.7150/ntno.19935. 
[53] H.S. Hwang, H. Shin, J. Han, K. Na, Combination of 
photodynamic therapy (PDT) and anti-tumor 
immunity in cancer therapy, J. Pharm. Investig. 48 
(2018) 143–151. https://doi.org/10.1007/s40005-017-
0377-x. 
[54] Y. Zhang, N. Zhang, R.M. Hoffman, M. Zhao, 
Surgically-induced multi-organ metastasis in an 
orthotopic syngeneic imageable model of 4T1 murine 
breast cancer, Anticancer Res. 35 (2015) 4641–4646. 
[55] K. Sztandera, M. Gorzkiewicz, B. Klajnert-
Maculewicz, Nanocarriers in photodynamic therapy—
in vitro and in vivo studies, WIREs Nanomedicine 
and Nanobiotechnology. n/a (2019) e1509. 
https://doi.org/10.1002/wnan.1599. 
[56] F. Chen, W. Bu, W. Cai, J. Shi, Functionalized 
upconversion nanoparticles: versatile nanoplatforms 
for translational research, Curr. Mol. Med. 13 (2013) 
1613–1632. 
https://doi.org/10.2174/156652401366613111112213
3. 
[57] S.R. Rice, Y.R. Li, T.M. Busch, M.M. Kim, S. 
McNulty, A. Dimofte, T.C. Zhu, K.A. Cengel, C.B. 
Simone, A Novel Prospective Study Assessing the 
Combination of Photodynamic Therapy and Proton 
Radiation Therapy: Safety and Outcomes When 
Treating Malignant Pleural Mesothelioma, 
Photochem. Photobiol. 95 (2019) 411–418. 
https://doi.org/10.1111/php.13065. 
[58] M. Grigalavicius, M. Mastrangelopoulou, K. Berg, D. 
Arous, M. Menard, T. Raabe-Henriksen, E. Brondz, 
S. Siem, A. Gorgen, N.F.J. Edin, E. Malinen, T.A. 
Theodossiou, Proton-dynamic therapy following 
photosensitiser activation by accelerated protons 
demonstrated through fluorescence and singlet 
oxygen production, Nat. Commun. 10 (2019) 3986. 
https://doi.org/10.1038/s41467-019-12042-7. 
[59] D.K. Deda, K. Araki, Nanotechnology, light and 
chemical action: An effective combination to kill 
cancer cells, J. Braz. Chem. Soc. 26 (2015) 2448–
2470. https://doi.org/10.5935/0103-5053.20150316. 
[60] B.L. Hylander, J.W.-L. Eng, E.A. Repasky, The 
impact of housing temperature-induced chronic stress 
on preclinical mouse tumor models and therapeutic 
responses: An important role for the nervous system, 
Adv. Exp. Med. Biol. 1036 (2017) 173–189. 
https://doi.org/10.1007/978-3-319-67577-0_12. 
 
